Holtzman was nominated for his work on Alzheimer’s disease. He has dedicated more than 20 years to trying to discover new therapies to help people with the disease. He co-founded a biotechnology company (C2N Diagnostics) which helps track how well drugs work in clinical studies. There are also two large AD prevention studies going on using one of his antibodies, developed by Lilly.
As winner of the Watanabe Prize, Holtzman will be the featured speaker at the Indiana CTSI Annual Meeting, which will be focused on Alzheimer’s disease and neurological disorders. Holtzman will also serve as a long-distance mentor to two young investigators, who will give presentations during the meeting.
Anyone interested in attending the Indiana CTSI Annual Meeting, please register here.
Investigators who would like to present posters during the event can apply online. The deadline to apply for poster presentations is August 16. Presenters will be notified of their acceptance by August 23.